HRP20150524T1 - Protutijela za il-25 - Google Patents
Protutijela za il-25 Download PDFInfo
- Publication number
- HRP20150524T1 HRP20150524T1 HRP20150524TT HRP20150524T HRP20150524T1 HR P20150524 T1 HRP20150524 T1 HR P20150524T1 HR P20150524T T HRP20150524T T HR P20150524TT HR P20150524 T HRP20150524 T HR P20150524T HR P20150524 T1 HRP20150524 T1 HR P20150524T1
- Authority
- HR
- Croatia
- Prior art keywords
- gly
- ser
- val
- tyr
- thr
- Prior art date
Links
- 238000000034 method Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- SVBXIUDNTRTKHE-CIUDSAMLSA-N Ala-Arg-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O SVBXIUDNTRTKHE-CIUDSAMLSA-N 0.000 claims 2
- WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 claims 2
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 claims 2
- ZJLORAAXDAJLDC-CQDKDKBSSA-N Ala-Tyr-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O ZJLORAAXDAJLDC-CQDKDKBSSA-N 0.000 claims 2
- FEZJJKXNPSEYEV-CIUDSAMLSA-N Arg-Gln-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O FEZJJKXNPSEYEV-CIUDSAMLSA-N 0.000 claims 2
- OTZMRMHZCMZOJZ-SRVKXCTJSA-N Arg-Leu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OTZMRMHZCMZOJZ-SRVKXCTJSA-N 0.000 claims 2
- SUIJFTJDTJKSRK-IHRRRGAJSA-N Asn-Pro-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 SUIJFTJDTJKSRK-IHRRRGAJSA-N 0.000 claims 2
- YQPSDMUGFKJZHR-QRTARXTBSA-N Asn-Trp-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)N)N YQPSDMUGFKJZHR-QRTARXTBSA-N 0.000 claims 2
- GCACQYDBDHRVGE-LKXGYXEUSA-N Asp-Thr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC(O)=O GCACQYDBDHRVGE-LKXGYXEUSA-N 0.000 claims 2
- HTSSXFASOUSJQG-IHPCNDPISA-N Asp-Tyr-Trp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O HTSSXFASOUSJQG-IHPCNDPISA-N 0.000 claims 2
- OZHXXYOHPLLLMI-CIUDSAMLSA-N Cys-Lys-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OZHXXYOHPLLLMI-CIUDSAMLSA-N 0.000 claims 2
- PONUFVLSGMQFAI-AVGNSLFASA-N Gln-Asn-Phe Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PONUFVLSGMQFAI-AVGNSLFASA-N 0.000 claims 2
- VMKCPNBBPGGQBJ-GUBZILKMSA-N Glu-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N VMKCPNBBPGGQBJ-GUBZILKMSA-N 0.000 claims 2
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 claims 2
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 claims 2
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 claims 2
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 claims 2
- LRQXRHGQEVWGPV-NHCYSSNCSA-N Gly-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN LRQXRHGQEVWGPV-NHCYSSNCSA-N 0.000 claims 2
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 claims 2
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 claims 2
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 claims 2
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 claims 2
- GILLQRYAWOMHED-DCAQKATOSA-N Lys-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN GILLQRYAWOMHED-DCAQKATOSA-N 0.000 claims 2
- 108010079364 N-glycylalanine Proteins 0.000 claims 2
- JNRFYJZCMHHGMH-UBHSHLNASA-N Phe-Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 JNRFYJZCMHHGMH-UBHSHLNASA-N 0.000 claims 2
- JMVQDLDPDBXAAX-YUMQZZPRSA-N Pro-Gly-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 JMVQDLDPDBXAAX-YUMQZZPRSA-N 0.000 claims 2
- HJEBZBMOTCQYDN-ACZMJKKPSA-N Ser-Glu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HJEBZBMOTCQYDN-ACZMJKKPSA-N 0.000 claims 2
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 claims 2
- OQPNSDWGAMFJNU-QWRGUYRKSA-N Ser-Gly-Tyr Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OQPNSDWGAMFJNU-QWRGUYRKSA-N 0.000 claims 2
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 claims 2
- PQEQXWRVHQAAKS-SRVKXCTJSA-N Ser-Tyr-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)N)CC1=CC=C(O)C=C1 PQEQXWRVHQAAKS-SRVKXCTJSA-N 0.000 claims 2
- JKGGPMOUIAAJAA-YEPSODPASA-N Thr-Gly-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O JKGGPMOUIAAJAA-YEPSODPASA-N 0.000 claims 2
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 claims 2
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 claims 2
- JWHOIHCOHMZSAR-QWRGUYRKSA-N Tyr-Asp-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JWHOIHCOHMZSAR-QWRGUYRKSA-N 0.000 claims 2
- OLYXUGBVBGSZDN-ACRUOGEOSA-N Tyr-Leu-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 OLYXUGBVBGSZDN-ACRUOGEOSA-N 0.000 claims 2
- XFEMMSGONWQACR-KJEVXHAQSA-N Tyr-Thr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O XFEMMSGONWQACR-KJEVXHAQSA-N 0.000 claims 2
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 claims 2
- LCHZBEUVGAVMKS-RHYQMDGZSA-N Val-Thr-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(O)=O LCHZBEUVGAVMKS-RHYQMDGZSA-N 0.000 claims 2
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 claims 2
- 108010086434 alanyl-seryl-glycine Proteins 0.000 claims 2
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 claims 2
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 108010038745 tryptophylglycine Proteins 0.000 claims 2
- 108010073969 valyllysine Proteins 0.000 claims 2
- 108010009962 valyltyrosine Proteins 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Claims (15)
1. Ciljani vezni element koji se veže na IL-25, naznačen time, da obuhvaća VL-domenu protutijela koja sadrži Kabat-CDR-ove 1-3 koji su predstavljeni od SEQ ID NO:15 kao ostatci 24-34 (SEQ ID NO:29); odnosno 50-56 (SEQ ID NO:30); odnosno 89-97 (SEQ ID NO:31), te VH-domenu protutijela koja sadrži SEQ ID NO:1:
Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr
Ser Phe Xa1 Xa2 Tyr Thr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Xa3 Gly Leu Ile Asn Pro
Tyr Asn Gly Gly Thr Ser Tyr Asn Gln Asn Phe Lys Gly Arg Val Thr Leu Thr Xa4 Asp Thr Ser Ala Ser Thr Ala
Tyr Leu Glu Leu Asn Ser Leu Arg Ser Glu Asp Thr Gly Val Tyr Tyr Cys Ala Arg Glu Xa5 Tyr Asp Gly Tyr Leu
Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
pri čemu:
Xa1 je Ser ili Thr;
Xa2 je Gly, Asp, Ala, Ser, Val, Asn, Lys, Tyr ili Met;
Xa3 je Met ili Ile;
Xa4 je Val ili Arg; i
Xa5 je Asp, Asn ili Gly.
2. Ciljani vezni element prema zahtjevu 1, naznačen time, da
(a) Xa2 je Gly i Xa5 je Asp ili Asn;
(b) Xa2 je Gly i Xa5 je Asp;
(c) Xa1 je Ser;
(d) Xa1 je Thr;
(e) Xa3 je Met;
(f) Xa3 je Ile;
(g) Xa4 je Val; ili
(h) Xa4 je Arg.
3. Ciljani vezni element prema zahtjevu 1, naznačen time, da su ostatci Xa1 – Xa5 u sljedećim kombinacijama:
[image]
4. Ciljani vezni element prema zahtjevu 1, naznačen time, da
a) VL-domena nadalje uključuje ostatke 35-38 od SEQ ID NO:15 granične uz CDR1 (SEQ ID NO:29);
b) uključuje SEQ ID NO:15;
c) VL-domena je humanizirana; ili
d) VL-domena je humanizirana, a sekvenca od ciljanog veznog elementa sadrži aminokiseline 21-127 od SEQ ID NO:25.
5. Ciljani vezni element prema zahtjevu 1, naznačen time, da je to sljedeći fragment protutijela: Fab, F(ab')2, scFv ili Fv.
6. Ciljani vezni element prema zahtjevu 1, naznačen time, da sadrži konstantno područje protutijela.
7. Ciljani vezni element prema zahtjevu 6, naznačen time, da konstantno područje je konstantno područje ljudskog IgG1 ili IgG4.
8. Izolirana nukleinska kiselina, naznačena time, da obuhvaća nukleotidnu sekvencu koja kodira ciljani vezni element prema zahtjevu 1.
9. Vektor ekspresije, naznačen time, da obuhvaća nukleinsku kiselinu prema zahtjevu 8, koja je radno povezana na pokretač.
10. Stanica domaćina, naznačena time, da prenosi vektor ekspresije prema zahtjevu 9.
11. Postupak proizvodnje ciljanog veznog elementa, naznačen time, da postupak obuhvaća kultiviranje stanice domaćina prema zahtjevu 10, pod prikladnim uvjetima za proizvodnju navedenog ciljanog veznog elementa, pri čemu postupak po želji dalje obuhvaća izoliranje navedenog ciljanog veznog elementa, te po želji nadalje obuhvaća formuliranje ciljanog veznog elementa u sastav koji uključuje najmanje jedan dodatni sastojak.
12. Sastav, naznačen time, da obuhvaća ciljani vezni element prema zahtjevu 1 i farmaceutski prihvatljiv nosač, pri čemu je taj sastav po želji u obliku liofiliziranog praška.
13. Ciljani vezni element prema bilo kojem od zahtjeva 1 do 7, naznačen time, da se upotrebljava u liječenju ili prevenciji sljedećih stanja:
(a) astma;
(b) upalna bolest crijeva;
(c) ulcerativni kolitis; ili
(d) Chronova bolest.
14. Postupak proizvodnje protutijela za IL-25, naznačen time, da obuhvaća:
(a) stvaranje VH-domene protutijela koja sadrži SEQ ID NO:1:
Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr
Ser Phe Xa1 Xa2 Tyr Thr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Xa3 Gly Leu Ile Asn Pro
Tyr Asn Gly Gly Thr Ser Tyr Asn Gln Asn Phe Lys Gly Arg Val Thr Leu Thr Xa4 Asp Thr Ser Ala Ser Thr Ala
Tyr Leu Glu Leu Asn Ser Leu Arg Ser Glu Asp Thr Gly Val Tyr Tyr Cys Ala Arg Glu Xa5 Tyr Asp Gly Tyr Leu
Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
pri čemu:
Xa1 je Ser ili Thr;
Xa2 je Gly, Asp, Ala, Ser, Val, Asn, Lys, Tyr ili Met;
Xa3 je Met ili Ile;
Xa4 je Val ili Arg; i
Xa5 je Asp, Asn ili Gly.
(b) sastavljanje VH-domene s većim brojem VL-domena protutijela za dobivanje molekula protutijela;
(c) screening navedenih molekula protutijela za vezanje sa IL-25; i
(d) selektiranje molekule protutijela, koja se veže za IL-25.
15. Ciljani vezni element prema zahtjevu 1, naznačen time, da on obuhvaća cijelo protutijelo.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10129308P | 2008-09-30 | 2008-09-30 | |
| GBGB0817891.5A GB0817891D0 (en) | 2008-09-30 | 2008-09-30 | Antibodies against il-25 |
| PCT/IB2009/007302 WO2010038155A2 (en) | 2008-09-30 | 2009-09-30 | Antibodies against il-25 |
| EP09795802.9A EP2344538B1 (en) | 2008-09-30 | 2009-09-30 | Antibodies against il-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150524T1 true HRP20150524T1 (hr) | 2015-08-14 |
Family
ID=40019808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150524TT HRP20150524T1 (hr) | 2008-09-30 | 2015-05-15 | Protutijela za il-25 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8658169B2 (hr) |
| EP (1) | EP2344538B1 (hr) |
| JP (1) | JP5719771B2 (hr) |
| KR (1) | KR101659452B1 (hr) |
| CN (1) | CN102245638B (hr) |
| AU (1) | AU2009299465B2 (hr) |
| BR (1) | BRPI0919062A2 (hr) |
| CA (1) | CA2739050C (hr) |
| CY (1) | CY1116313T1 (hr) |
| DK (1) | DK2344538T3 (hr) |
| ES (1) | ES2537226T3 (hr) |
| GB (1) | GB0817891D0 (hr) |
| HK (1) | HK1154022A1 (hr) |
| HR (1) | HRP20150524T1 (hr) |
| ME (1) | ME02219B (hr) |
| MX (1) | MX2011003351A (hr) |
| NZ (1) | NZ592274A (hr) |
| PL (1) | PL2344538T3 (hr) |
| PT (1) | PT2344538E (hr) |
| RS (1) | RS54028B1 (hr) |
| SI (1) | SI2344538T1 (hr) |
| SM (1) | SMT201500144B (hr) |
| WO (1) | WO2010038155A2 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0707505D0 (en) | 2007-04-18 | 2007-05-30 | Medical Res Council | Antibodies against il-25 |
| GB0817891D0 (en) | 2008-09-30 | 2008-11-05 | Medical Res Council | Antibodies against il-25 |
| EA031203B1 (ru) | 2010-03-30 | 2018-11-30 | Янссен Байотек Инк. | Гуманизированные антитела к il-25 |
| WO2013118878A1 (ja) * | 2012-02-09 | 2013-08-15 | 独立行政法人理化学研究所 | 環状ｒｎａ及びタンパク質の製造方法 |
| CN103792375B (zh) * | 2014-01-29 | 2017-07-07 | 华中科技大学同济医学院附属同济医院 | 外周血白细胞介素25水平在哮喘分型中的应用及分型方法 |
| CN107207589B (zh) * | 2014-09-23 | 2021-04-06 | 瑞泽恩制药公司 | 抗il-25抗体及其使用方法 |
| US11492397B2 (en) * | 2016-03-16 | 2022-11-08 | Abeome Corporation | Neutralizing monoclonal antibodies to IL-25 and uses thereof |
| WO2018017864A2 (en) * | 2016-07-20 | 2018-01-25 | Oncomed Pharmaceuticals, Inc. | Pvrig-binding agents and uses thereof |
| WO2018018082A1 (en) | 2016-07-26 | 2018-02-01 | The Australian National University | Immunostimulatory compositions and uses therefor |
| KR102598319B1 (ko) * | 2018-11-19 | 2023-11-02 | 쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 | 항-il-25 항체 및 그의 용도 |
| GB202018015D0 (en) | 2020-11-16 | 2020-12-30 | Res & Innovation Uk | Composition and methods for the treatment of intestinal cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US5071972A (en) | 1986-01-31 | 1991-12-10 | Genetics Institute, Inc. | DNA sequences encoding novel thrombolytic proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| EP0276846A3 (en) | 1987-01-29 | 1989-07-26 | Zymogenetics, Inc. | Colony-stimulating factor derivatives |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
| US6569645B2 (en) | 1999-05-14 | 2003-05-27 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| ATE517920T1 (de) | 2003-04-23 | 2011-08-15 | Medarex Inc | Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1) |
| EP1863520B1 (en) | 2005-03-08 | 2014-12-31 | Aptose Biosciences Inc. | Use of interleukin 17e for the treatment of cancer |
| WO2007044450A2 (en) | 2005-10-06 | 2007-04-19 | Baylor Research Institute | Compositions and methods for the treatment of cancer |
| GB0707505D0 (en) | 2007-04-18 | 2007-05-30 | Medical Res Council | Antibodies against il-25 |
| GB0817891D0 (en) | 2008-09-30 | 2008-11-05 | Medical Res Council | Antibodies against il-25 |
| EA031203B1 (ru) * | 2010-03-30 | 2018-11-30 | Янссен Байотек Инк. | Гуманизированные антитела к il-25 |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2008
- 2008-09-30 GB GBGB0817891.5A patent/GB0817891D0/en not_active Ceased
-
2009
- 2009-09-30 KR KR1020117009937A patent/KR101659452B1/ko active IP Right Grant
- 2009-09-30 EP EP09795802.9A patent/EP2344538B1/en active Active
- 2009-09-30 BR BRPI0919062A patent/BRPI0919062A2/pt not_active Application Discontinuation
- 2009-09-30 WO PCT/IB2009/007302 patent/WO2010038155A2/en active Application Filing
- 2009-09-30 JP JP2011528454A patent/JP5719771B2/ja active Active
- 2009-09-30 DK DK09795802.9T patent/DK2344538T3/en active
- 2009-09-30 NZ NZ592274A patent/NZ592274A/xx not_active IP Right Cessation
- 2009-09-30 PL PL09795802T patent/PL2344538T3/pl unknown
- 2009-09-30 AU AU2009299465A patent/AU2009299465B2/en active Active
- 2009-09-30 CN CN200980147932.6A patent/CN102245638B/zh active Active
- 2009-09-30 SI SI200931196T patent/SI2344538T1/sl unknown
- 2009-09-30 PT PT97958029T patent/PT2344538E/pt unknown
- 2009-09-30 RS RS20150341A patent/RS54028B1/en unknown
- 2009-09-30 US US13/121,898 patent/US8658169B2/en active Active
- 2009-09-30 CA CA2739050A patent/CA2739050C/en active Active
- 2009-09-30 ES ES09795802.9T patent/ES2537226T3/es active Active
- 2009-09-30 ME MEP-2015-78A patent/ME02219B/me unknown
- 2009-09-30 MX MX2011003351A patent/MX2011003351A/es active IP Right Grant
-
2011
- 2011-08-08 HK HK11108260.3A patent/HK1154022A1/xx unknown
-
2015
- 2015-05-15 HR HRP20150524TT patent/HRP20150524T1/hr unknown
- 2015-05-22 CY CY20151100460T patent/CY1116313T1/el unknown
- 2015-06-18 SM SM201500144T patent/SMT201500144B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009299465A1 (en) | 2010-04-08 |
| US20110250195A1 (en) | 2011-10-13 |
| JP2012503979A (ja) | 2012-02-16 |
| BRPI0919062A2 (pt) | 2015-12-15 |
| ME02219B (me) | 2016-02-20 |
| PT2344538E (pt) | 2015-06-19 |
| KR20110086013A (ko) | 2011-07-27 |
| US8658169B2 (en) | 2014-02-25 |
| RS54028B1 (en) | 2015-10-30 |
| SI2344538T1 (sl) | 2015-07-31 |
| CY1116313T1 (el) | 2017-02-08 |
| CA2739050C (en) | 2018-05-29 |
| ES2537226T3 (es) | 2015-06-03 |
| DK2344538T3 (en) | 2015-06-01 |
| CA2739050A1 (en) | 2010-04-08 |
| CN102245638B (zh) | 2014-10-22 |
| SMT201500144B (it) | 2015-09-07 |
| EP2344538B1 (en) | 2015-02-25 |
| HK1154022A1 (en) | 2012-04-13 |
| JP5719771B2 (ja) | 2015-05-20 |
| AU2009299465B2 (en) | 2012-07-26 |
| EP2344538A2 (en) | 2011-07-20 |
| MX2011003351A (es) | 2011-05-25 |
| PL2344538T3 (pl) | 2015-10-30 |
| CN102245638A (zh) | 2011-11-16 |
| NZ592274A (en) | 2012-08-31 |
| WO2010038155A2 (en) | 2010-04-08 |
| WO2010038155A3 (en) | 2010-05-27 |
| GB0817891D0 (en) | 2008-11-05 |
| KR101659452B1 (ko) | 2016-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150524T1 (hr) | Protutijela za il-25 | |
| KR101836217B1 (ko) | Ｉｌ-１７ａ 길항제 | |
| AU2008300028B2 (en) | Antigen binding proteins capable of binding thymic stromal lymphopoietin | |
| HRP20161548T1 (hr) | Protutijela za il-25 | |
| KR101683033B1 (ko) | 톨-유사 수용체 3 길항제 | |
| JP2012503979A5 (hr) | ||
| EP3233922B1 (en) | Blood brain barrier transport molecules and uses thereof | |
| DK2897978T3 (en) | PROCEDURES FOR IDENTIFYING ANTIBODIES WITH REDUCED IMMUNOGENICITY | |
| CA3020647A1 (en) | Anti-tim-3 antibodies and compositions | |
| US20120329995A1 (en) | Novel Lowered Affinity Antibodies And Methods of Making the Same | |
| KR101739489B1 (ko) | 인간 유래 항-인간 표피 생장인자 수용체 항체 및 그의 코딩 유전자와 용도 | |
| CA2585043A1 (en) | High affinity antibodies against hmgb1 and methods of use thereof | |
| SG178335A1 (en) | Antibodies against human respiratory syncytial virus (rsv) and methods of use | |
| CA2744065A1 (en) | Process for the modulation of the antagonistic activity of a monoclonal antibody | |
| CN103429616A (zh) | 结合人胶原ii的抗体 | |
| EP2425008B1 (en) | Toll-like receptor 3 antagonists | |
| EP3170839B1 (en) | POLYMERIC IgA-TYPE RECOMBINANT ANTIBODY AND USE THEREOF | |
| CN107987166A (zh) | 针对组织因子途径抑制剂(tfpi)的优化的单克隆抗体 | |
| CN107667114A (zh) | 中和抗流感结合分子及其用途 | |
| EP2900266A1 (en) | Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases | |
| KR20140108520A (ko) | CD1d에 대한 항체 | |
| CA3185253A1 (en) | Anti-surrogate light chain antibodies | |
| US20230416394A1 (en) | Novel conjugate molecules targeting cd39 and tgfbeta | |
| CN113728006B (zh) | 新型抗ifnar1抗体 | |
| CN113784984A (zh) | 抗SIRPα抗体 |